PMID- 26873651
OWN - NLM
STAT- MEDLINE
DCOM- 20170330
LR  - 20220316
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 25
IP  - 9
DP  - 2016 Aug
TI  - Predicting decline of kidney function in lupus nephritis using urine biomarkers.
PG  - 1012-8
LID - 10.1177/0961203316631629 [doi]
AB  - OBJECTIVE: To evaluate candidate biomarkers to predict future renal function 
      decline (RFD) in children and adults with lupus nephritis (LN). METHODS: At the 
      time of enrollment into prospective observational LN cohort studies liver-type 
      fatty acid binding protein (LFABP), albumin, monocyte chemoattractant protein-1 
      (MCP-1), uromodulin, transferrin, and hepcidin were measured in urine samples of 
      two cohorts of patients with LN, one followed at a pediatric (cohort-1; n = 28) 
      and one at an adult institution (cohort-2; n = 69). The primary outcome was RFD, 
      defined in cohort-1 as a decrease in estimated glomerular filtration rate (eGFR) 
      of >/=20% and in cohort-2 as a sustained increase of >/=25% in serum creatinine 
      concentration (SCr), both from baseline. RESULTS: All patients (n = 97) had 
      normal eGFR or SCr at the time of urine collection at baseline. RFD occurred in 
      29% (8/28) of patients in cohort-1 during a mean follow-up of 6.1 months, and in 
      30% (21/69) of those in cohort-2 during a mean follow-up of 60 months. 
      Individually, in cohort-1, levels of MCP-1, transferrin, LFABP, and albumin were 
      higher in the RFD group than those who maintained renal function, with 
      statistical significance for LFABP and albumin. In cohort-2 the RFD group also 
      had higher levels of urine MCP-1 and albumin than others. The combination of 
      LFABP, MCP-1, albumin, and transferrin had good predictive accuracy for RFD in 
      both cohorts (area under the ROC curve = 0.77-0.82). CONCLUSION: The 
      combinatorial urine biomarker LFABP, MCP-1, albumin, and transferrin shows 
      promise as a predictor of renal functional decline in LN, and warrants further 
      investigation.
CI  - (c) The Author(s) 2016.
FAU - Abulaban, K M
AU  - Abulaban KM
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      Cincinnati, USA Department of Pediatrics, Helen DeVos Childrens Hospital, 
      Michigan State University, Grand Rapids, USA.
FAU - Song, H
AU  - Song H
AD  - Department of Internal Medicine, Ohio State University Wexner Medical Center, 
      Columbus, USA.
FAU - Zhang, X
AU  - Zhang X
AD  - Department of Internal Medicine, Ohio State University Wexner Medical Center, 
      Columbus, USA.
FAU - Kimmel, P L
AU  - Kimmel PL
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
FAU - Kusek, J W
AU  - Kusek JW
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
FAU - Nelson, R G
AU  - Nelson RG
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, USA.
FAU - Feldman, H I
AU  - Feldman HI
AD  - Department of Epidemiology and Biostatistics, University of Pennsylvania, 
      Philadelphia, USA.
FAU - Vasan, R S
AU  - Vasan RS
AD  - Preventive Medicine and Cardiology Sections, and Department of Medicine, Boston 
      University School of Medicine, Boston, USA.
FAU - Ying, J
AU  - Ying J
AD  - Department of Environmental Health, University of Cincinnati, Cincinnati, USA.
FAU - Mauer, M
AU  - Mauer M
AD  - Department of Pediatrics, University of Minnesota, Minneapolis, USA.
FAU - Nelsestuen, G L
AU  - Nelsestuen GL
AD  - Department of Pediatrics, University of Minnesota, Minneapolis, USA.
FAU - Bennett, M
AU  - Bennett M
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      Cincinnati, USA.
FAU - Brunner, H I
AU  - Brunner HI
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      Cincinnati, USA.
FAU - Rovin, B H
AU  - Rovin BH
AD  - Department of Internal Medicine, Ohio State University Wexner Medical Center, 
      Columbus, USA Brad.Rovin@osumc.edu.
LA  - eng
GR  - P50 DK096418/DK/NIDDK NIH HHS/United States
GR  - U01 DK085673/DK/NIDDK NIH HHS/United States
GR  - U01 DK096927/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20160211
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hepcidins)
RN  - 0 (Transferrin)
RN  - 0 (UMOD protein, human)
RN  - 0 (Uromodulin)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers/urine
MH  - Chemokine CCL2/urine
MH  - Child
MH  - Creatinine/urine
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Hepcidins/urine
MH  - Humans
MH  - Kidney Function Tests
MH  - Lupus Nephritis/diagnosis/*physiopathology/*urine
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Transferrin/urine
MH  - Uromodulin/urine
MH  - Young Adult
PMC - PMC4945408
MID - NIHMS753584
OTO - NOTNLM
OT  - SLE
OT  - biomarker
OT  - kidney injury
OT  - lupus nephritis
OT  - renal function decline
EDAT- 2016/02/14 06:00
MHDA- 2017/03/31 06:00
PMCR- 2017/08/01
CRDT- 2016/02/14 06:00
PHST- 2015/04/21 00:00 [received]
PHST- 2016/01/14 00:00 [accepted]
PHST- 2016/02/14 06:00 [entrez]
PHST- 2016/02/14 06:00 [pubmed]
PHST- 2017/03/31 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - 0961203316631629 [pii]
AID - 10.1177/0961203316631629 [doi]
PST - ppublish
SO  - Lupus. 2016 Aug;25(9):1012-8. doi: 10.1177/0961203316631629. Epub 2016 Feb 11.